Annual Report for FY 2024 - 25
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Shree Ganesh Remedies Limited submitted its Annual Report for FY 2024-25 and notice of its 30th AGM, scheduled for September 9, 2025 via video conferencing. The company, which manufactures pharmaceutical intermediates and speciality chemicals, reported FY25 revenue of ₹108.60 crore, a decline of about 14% from ₹125.90 crore in FY24, due to weak demand in Europe and sharp price erosion in India (25-30% lower realisations domestically). Despite the revenue dip, EBITDA grew to ₹39.21 crore with margins expanding roughly 290 basis points to 36.1%, supported by higher contribution from high-margin CRAMS projects. Profit after tax stood at ₹23.10 crore versus ₹30.45 crore in FY24, with the decline attributed to higher depreciation and finance costs from new capacity. ROCE remained healthy at 33.2%, and the company maintained a lean balance sheet with debt-equity of 0.26x.
Shareholders should note the FY25 revenue contraction alongside a margin improvement, reflecting a strategic shift toward higher-value speciality chemicals. The upcoming AGM and e-voting window (September 6-8) allow shareholder participation, while ongoing investments in Dahej, Block 7 at Ankleshwar, and a new pilot plant signal a near-term capex-heavy phase with growth expected to ramp up from FY27 onward.